Filing Flows › Keros Therapeutics (KROS) › Q3 2026
Keros Therapeutics (KROS) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Keros Therapeutics (KROS) reported revenue of $40.0M for the third quarter 2026 (Q3 2026), +183% from a year earlier. Operating margin was 32.0%, net earnings $14.2M (35.4% of revenue).
Keros Therapeutics, Q3 2026: revenue $40.0M (+183% year over year), operating margin 32.0%, net earnings $14.2M, operating cash flow $3.4M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $40.0M | — | +183% |
| Operating profit | $12.8M | — | — |
| Net earnings | $14.2M | — | — |
| Operating cash flow | $3.4M | — | +4% |
| Free cash flow | $3.3M | — | +7% |
What changed
Revenue was $40.0M in Q3 2026, up 183% year over year.
Operating profit was $12.8M, a 32.0% margin (up 141.0 points year over year). Total costs fell 8% while revenue rose 183%. Net earnings were $14.2M. The effective tax rate was 5.2%.
Operating cash flow was $3.4M (up 4% year over year), 24% of net earnings. Non-cash charges added back $384K of depreciation and $4.2M of share-based compensation. Working capital and other items used $15.3M. Capital expenditures of $59K left free cash flow of $3.3M.
Questions
What was Keros Therapeutics' revenue in the third quarter 2026?
Keros Therapeutics (KROS) reported revenue of $40.0M for the third quarter 2026 (Q3 2026), +183% from a year earlier.
Was Keros Therapeutics profitable in the third quarter 2026?
Operating profit was $12.8M (32.0% of revenue) and net earnings $14.2M.
Source: Keros Therapeutics 10-Q on SEC EDGAR.